Navigation Links
DNA Analysis Could Help Customize Treatments for MS
Date:1/16/2008

Study suggests it could show who will respond best to interferon beta treatments

WEDNESDAY, Jan. 16 (HealthDay News) -- Genetic differences might explain why some multiple sclerosis (MS) patients respond to treatment while others don't, suggests an international study.

Starting with 206 southern European patients with relapsing-remitting MS, the most common form of the disease, the researchers compared the DNA of patients whose symptoms were reduced by interferon beta therapy to the DNA of those who experienced relapses after such therapy. They were able to identify important genetic differences between the two groups of patients.

Those differences could eventually be used to help predict which MS treatments will benefit which patients, the study authors said. MS is a neurological disorder in which nerve fiber coatings degenerate, which leads to muscle weakness and possible paralysis.

The findings appeared in the Jan. 14 online issue of the Archives of Neurology and were expected to be published in the March print issue of the journal.

"The beneficial outcomes of interferon beta therapy for patients in the relapsing-remitting phase of MS have been clearly shown," the researchers wrote. "On the other hand, the effect of this treatment is partial, and a substantial amount of patients (up to 50 percent) are not responders. Hence, in the absence of prognostic clinical, neuroradiological and/or immunological markers of response, the question remains who and when to treat when adverse effects, inconvenience and the cost of drugs are significant."

More research is needed to fully predict MS treatment outcomes based on patient DNA analysis, the researchers added.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about MS.



-- Robert Preidt



SOURCE: JAMA/Archives journals, news release, Jan. 14, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Congressional Budget Office Analysis of HR971 Rejects Pharmacy Benefit Managers Bogus Claim Bill Would Cost $29 Billion Over 5 Years
2. PCMA: New CBO Analysis Confirms Independent Pharmacy Collective Bargaining Legislation Increases Costs for Consumers and Payors
3. Working with children with autistic spectrum disorder: Psychoanalysis and neurobiology
4. Uses of medications in psychoanalysis
5. First rigorous analysis defines impact of Medicare Part D
6. Updated Analysis of 2001 Epoetin Alfa Study Posted
7. Biolytix to Offer Industrial Gene Expression Analysis and Genotyping Services Using Affymetrix GeneChip(R) Technology
8. Ranking Americas Mental Health: An Analysis of Depression Across the States
9. Amarin Announces Completion of Comprehensive Data Analysis From Phase III Huntingtons Disease Program
10. Long-term pharmacotherapy for obesity and overweight: updated meta-analysis
11. Center For Excellence to Fund Analysis of Michigan State Retiree Health Care Reforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... PurhealthRX , a leading Health and Nutrition Company, is announcing ... full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the ... incorporated into liquid products, while reducing costs to end users. , The team of ...
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... of the most popular and least understood books in the Holy Scriptures, Revelation. The ... that have baffled scholars for centuries. Many have tossed it off as mere rubbish, ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/22/2017)... SAN DIEGO , Sept. 22, 2017 ... ll medical device is now successfully helping those with ... Union. Fibromyalgia diagnosed Amanda in ... getting dressed and washing my hair, experiencing no sleep ... body in painful spasm… I cannot recommend [the AVACEN ...
Breaking Medicine Technology: